Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Endocrine 1

Conditions

Ovarian Neoplasms 34Uterine Cervical Neoplasms 24Fallopian Tube Neoplasms 18Endometrial Neoplasms 16Neoplasm Metastasis 10Lung Neoplasms 9Pancreatic Neoplasms 8Stomach Neoplasms 7Colorectal Neoplasms 7Carcinoma, Transitional Cell 7Breast Neoplasms 7Melanoma 6Carcinoma, Renal Cell 6Prostatic Neoplasms 5Esophageal Neoplasms 5Carcinosarcoma 5Carcinoma, Hepatocellular 5Vaginal Neoplasms 4Triple Negative Breast Neoplasms 4Thyroid Neoplasms 4Colonic Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Urinary Bladder Neoplasms 3Testicular Neoplasms 3Small Cell Lung Carcinoma 3Sarcoma 3Multiple Myeloma 3Cholangiocarcinoma 3Brain Neoplasms 3Vulvar Neoplasms 2

Interventions

Ifosfamide 3Doxorubicin 3Radiotherapy 2Imatinib Mesylate 2Filgrastim 2trebananib 1selurampanel 1selinexor 1saracatinib 1perifosine 1elacestrant 1Trabectedin 1Thalidomide 1Temozolomide 1Sunitinib 1RAD1901 1Postmortem Imaging 1Paclitaxel 1Mass Spectrometry 1Magnetic Resonance Spectroscopy 1Injections 1High-Energy Shock Waves 1Fulvestrant 1Cyproheptadine 1Chromatography, High Pressure Liquid 1Chemotherapy, Adjuvant 1Biopsy 1BI 2536 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma, Endometrial Stromal × Magnetic Resonance Spectroscopy × Gynecologic × Clear all
NCT02150213 2016-12-05

Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492

Novartis

Phase 2 Completed
59 enrolled 6 charts
EndocrineGynecologicSarcoma

Sarcoma, Endometrial Stromal, Adrenocortical Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡